Skip to main content
Premium Trial:

Request an Annual Quote

Europe s Affitech, Axaron Form Alliance to Develop Antibodies

NEW YORK, Dec. 4 – Affitech of Oslo and Axaron Bioscience of Heidelberg, Germany, said Tuesday that they had agreed to jointly develop and sel antibody drugs for neurological disorders. 

Axaron, formerly known as BASF-Lynx Bioscience, will use its transcription profiling technologies to identify targets that Affitech will then use in the development of antibodies. Both companies will support the effort to bring the antibodies through preclinical and clinical trials.

Affitech will have ownership of the antibodies, while Axaron, which will contribute some of the development costs, could be entitled to up to two-thirds of the profits from any products that are commercialized.  

The companies did not offer any specifics about the financial terms of the agreement.

Ole Marvik, CEO of Affitech, called the alliance “an excellent exsample of technical and commercial synergies.”

Established in 1997, Affitech generates human antibodies using an in vitro selection process.

Axaron grew out of a joint venture between German chemicals giant BASF and Lynx Therapeutics, an American maker of DNA profiling technologies.

The company's offerings are based on technologies developed in house as well as those licensed from Lynx Therapeutics, including Megaclone, a system that uses microbeads to sort millions of DNA molecules according to sequence, and Massively Parallel Signature Sequencing technology, which can identify genes by a 16 to 20 base signature sequence.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.